| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93b861c9b0ca08dc2536fc323cf40c29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eca0e196932bf1c3dab1740cf83ee673
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dfa2f6524cca615f3ab523afbe79097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7b85edf4e8b9338b24ad34ce53c7328
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6e999520480c2bf60cbc8507708084c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19dbd05e752c4bdcc42a64b8e1b19230 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2002-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_123e414db691245dda30b9f0aa4fc90f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bee27cc9a6b12bedd051f02e55f7e17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5595d05da63f0b091de8a5ba25c6f26f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_785223e746b7e619e53b9b73493733e8 |
| publicationDate |
2003-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03018617-A1 |
| titleOfInvention |
Method of purifying human mannose binding lectin, human mannose binding lectin compositions and medicinal use of human mannose binding lectin |
| abstract |
It is intended to provide a method of purifying MBL from a human plasma material at a high yield and a high purity; a method of producing at a high yield a composition containing highly pure MBL from a human plasma material; compositions containing highly pure MBL holding the high-dimension homooligomer structure produced by the above method; and novel use of MBL. A human plasma material is brought into contact with polyethylene glycol to give a clear MBL solution which is useful as a material for purifying MBL or as a material for producing MBL. Then the solution is subjected to affinity chromatography and heparin chromatography. MBL is useful in preventing or treating infections caused by cytomegalovirus and hepatitis B virus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019214555-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006046786-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004089394-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7084627-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021005500-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006522751-A |
| priorityDate |
2001-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |